These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32427616)

  • 1. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX; He YL
    Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.
    Xu L; Yu H; Xu S; Wang Y; Cao Y
    Skin Res Technol; 2024 May; 30(5):e13749. PubMed ID: 38776128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy.
    Liao SL; Yu M; Zhao ZT; Maurer M
    Front Immunol; 2021; 12():652973. PubMed ID: 33796115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
    Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
    Agache I; Rocha C; Pereira A; Song Y; Alonso-Coello P; Solà I; Beltran J; Posso M; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong P; O'Mahony L; Schwarze J; Werfel T; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2021 Jan; 76(1):59-70. PubMed ID: 32767573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
    Maurer M; Casale TB; Saini SS; Ben-Shoshan M; Giménez-Arnau AM; Bernstein JA; Yagami A; Stjepanovic A; Radin A; Staudinger HW; Patel N; Amin N; Akinlade B; Fan C; Bauer D; Yancopoulos GD; Patel K; Mannent LP; Laws E
    J Allergy Clin Immunol; 2024 Jul; 154(1):184-194. PubMed ID: 38431226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
    Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
    J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study.
    Hide M; Fukunaga A; Suzuki T; Nakamura N; Kimura M; Sasajima T; Kiriyama J; Igarashi A
    Allergol Int; 2023 Apr; 72(2):286-296. PubMed ID: 36272899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
    Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.
    Carrillo DC; Borges MS; García E; Egea E; Serrano CD
    World Allergy Organ J; 2014; 7(1):72. PubMed ID: 25566332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
    Apalla Z; Sidiropoulos T; Kampouropoulou E; Papageorgiou M; Lallas A; Lazaridou E; Smaragdi M; Delli F
    Eur J Dermatol; 2020 Dec; 30(6):716-722. PubMed ID: 33258453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria.
    Ornek S; Kocaturk E
    Cutan Ocul Toxicol; 2021 Dec; 40(4):305-311. PubMed ID: 34212792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
    Salman A; Comert E
    J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.
    Maurer M; Mathias SD; Crosby RD; Rajput Y; Zazzali JL
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):641-647. PubMed ID: 29567359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.